LivaNova (Nasdaq:LIVN) today increased its full-year sales and earnings guidance on strong second-quarter financial results.
The company now expects full-year revenue growth between 8% and 9%. It previously forecast between 7% and 8%. For adjusted earnings per share (EPS), the company now expects between $4.30 and $4.40, compared to a prior range of $4.20 to $4.30.
Shares of rose 0.7% to $85.93 apiece in pre-market trading today.
The Gloucester, England-based medtech company reported profits of $108.6 million. That equals $1.93 per share on sales of $390.6 million for the three months ended June 30, 2026.
LivaNova nearly quadrupled profits year-over-year on a sales increase of 10.8%. Cardiopulmonary delivered 11.2% revenue growth, while Neuromodulation sales rose 10.1% year-over-year.
Adjusted to exclude one-time items, earnings per share came in at $1.26. That landed 17¢ ahead of expectations on Wall Street. Sales also topped estimates as experts forecast $380.6 million in revenue.
Highlights in the quarter included sharing positive clinical findings for the company’s neuromodulation technology for treating sleep apnea, as well as the appointment of a new head of its Cardiopulmonary unit.
LivaNova also said today that it entered into a long-term agreement with Thermo Fisher Scientific to increase availability of a critical oxygenator component. It expects this to support increased oxygenator output over time.
“In the second quarter, LivaNova delivered strong revenue growth driven by sustained performance in our Cardiopulmonary and Epilepsy businesses,” said Vladimir Makatsaria, CEO of LivaNova. “We are also pleased to announce an agreement with Thermo Fisher Scientific, an important step in securing a critical component for our oxygenators, supporting the Cardiopulmonary supply chain long-term. Our updated 2026 guidance reflects strong execution in the core businesses as we advance our strategic plan and drive long-term value creation.”
